cubist
Merck launches new antibiotic in the UK
June 5, 2015Research and Development, Sales and Marketing AMR, Antibiotics, MSD, Merck, Sivextro, antimicrobial resistance, cubist, tedizolid phosphate
Merck has launched the first new drug in a class of antibiotics in the UK in almost 15 years, becoming …
Celgene appoints former Cubist chief executive
April 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, cubist, michael bonney
Celgene has elected pharma veteran Michael Bonney to join its board of directors. Bonney served as chief executive and board …
Cubist boosts antibiotics market presence
December 22, 2014Sales and Marketing Antibiotics, Zerbaxa, antimicrobial resistance, bacteria, cubist, infections, infectious diseases
Cubist has followed-up its successful European approval for a new antibiotic by winning an endorsement by the US FDA. The …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Updated: Merck buys antibiotics specialist Cubist
December 8, 2014Sales and Marketing Antibiotics, Merck, Novartis, cubicin, cubist, eumer
Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …
Cubist Pharmaceuticals names chief executive
October 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cubist, perez
US biopharma firm Cubist Pharmaceuticals has named Robert Perez as its chief executive and who will begin the role from …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
